[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352838-105":59,"doc-detail-352838-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liquid-biopsy-biomarkers-in-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-prostate-specific-membrane-antigen-radioligand-therapy-protocol-for-a-prospective-longitudinal-multicenter-observational-study","Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy - Protocol for a Prospective, Longitudinal Multicenter Observational Study","","Background: Prostate cancer causes high mortality in men worldwide. PSMA-targeted radioligand therapy (RLT) offers survival benefits, but responses vary and resistance mechanisms remain unclear. Liquid biopsy, especially circulating tumor DNA (ctDNA), may help assess tumor heterogeneity, monitor treatment effects, and detect emerging resistance. Objective: The LOOPS study prospectively evaluates prognostic and predictive ctDNA value during PSMA RLT. Methods: A multicenter trial recruits 100 mCRPC patients and longitudinally collects ctDNA, imaging, and clinical data. Primary and secondary endpoints evaluate response, ctDNA dynamics, and associations with baseline characteristics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liquid-biopsy-biomarkers-in-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-prostate-specific-membrane-antigen-radioligand-therapy-protocol-for-a-prospective-longitudinal-multicenter-observational-study/352838/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liquid-biopsy-biomarkers-in-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-prostate-specific-membrane-antigen-radioligand-therapy-protocol-for-a-prospective-longitudinal-multicenter-observational-study/352838.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary aim of the LOOPS study?","Question",{"text":112,"@type":113},"To prospectively investigate the prognostic and predictive value of ctDNA in patients receiving PSMA radioligand therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are ctDNA samples collected and assessed in the trial?",{"text":117,"@type":113},"Blood samples for ctDNA analysis are collected longitudinally at baseline and after cycles 1, 2, 4, and 6, using standardized processing protocols.",{"name":119,"@type":110,"acceptedAnswer":120},"What response endpoint does the study use to evaluate ctDNA?",{"text":121,"@type":113},"Baseline ctDNA’s prognostic and predictive value is assessed for treatment response based on imaging- and PSA-based criteria after 2 cycles of PSMA RLT.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352838,1790226609,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","| JMIR RESEARCH PROTOCOLS Michalski et al\u003Cbr>Protocol\u003Cbr>Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving ProstateSpecific Membrane Antigen Radioligand Therapy:\u003Cbr>Protocol for a Prospective, Longitudinal Multicenter Observational Study |\n| --- |\n|  |\n| Kerstin Michalski 1,2 , MD; Theo Lorenzini3 , MD; Tim Jedamzik 1 ; Marieke Heinrich 1 , MD; Aleksander Kosmala 1 , MD; Isabel Rauscher3 , MD Prof; Mika Bauch3 ; Lena Reichl4 ; Luisa Amann5 ; Simon Liebl4 ; Andreas Buck 1,2 , MD Prof; Matthias Eiber2,3 , MD Prof; Constantin Lapa2,5 , MD Prof; Rainer Claus2,4,6 , MD Prof |\n| 1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany 2Bavarian Cancer Research Center (BZKF), Erlangen, Germany\u003Cbr>3Department of Nuclear Medicine, School of Medicine and Health, Technical University of Munich, Munich, Germany 4Hematology and Oncology, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany\u003Cbr>5Department of Nuclear Medicine, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany 6Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany\u003Cbr>Corresponding Author:\u003Cbr>Kerstin Michalski, MD Department of Nuclear Medicine University Hospital Würzburg Oberdürrbacher Str. 6 Würzburg 97080\u003Cbr>Germany [Email:](Email: michalski_k@ukw.de)[ ](Email: michalski_k@ukw.de)[michalski_k@ukw.de](Email: michalski_k@ukw.de)\u003Cbr>Abstract |\n\nBackground: Prostate cancer is the second leading cause of cancer-related mortality in men worldwide. Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (RLT) has emerged as a theranostic strategy for metastatic castrationresistant prostate cancer (mCRPC), with [177Lu]Lu-PSMA-617 demonstrating survival benefits in the VISION trial. However, clinical responses are heterogeneous, and resistance mechanisms remain poorly understood. Liquid biopsy (LBx), particularly circulating tumor DNA (ctDNA), may provide a minimally invasive approach to assess tumor heterogeneity, monitor response, and detect emerging resistance.  \nObjective: The LOOPS (Liquid Biopsy as a Biomarker in Patients Treated with PSMA Radioligand Therapy) study aims to prospectively investigate the prognostic and predictive value of ctDNA in patients undergoing PSMA RLT.  \nMethods: LOOPS is a prospective, multicenter observational biomarker trial recruiting 100 patients with mCRPC eligible for PSMA RLT across 3 Bavarian cancer research centers in Germany. Patients will undergo up to 6 cycles of [177Lu]LuPSMA-617 . Blood samples for ctDNA analysis will be collected longitudinally (at baseline and after cycles 1, 2, 4, and 6) and processed according to standardized protocols. Imaging with PSMA positron emission tomography–computed tomography and clinical and biochemical data will be systematically collected. The primary end points are the prognostic and predictive value of baseline ctDNA for treatment response, defined by imaging- and prostate-specific antigen (PSA)–based response criteria after 2 cycles of PSMA RLT. Predictive performance will be evaluated using receiver operating characteristic analyses, including the determination of optimal ctDNA cutoffs, sensitivity, specificity, positive and negative predictive values, and multivariable logistic regression models adjusting for relevant clinical confounders. Secondary end points assess the concordance and correlation between ctDNA dynamics, systematically assessed PSMA positron emission tomography–computed tomography response, and PSA changes, as well as associations between ctDNA and clinical or laboratory (eg, age, Gleason score, and other) characteristics at baseline and during follow-up. Exploratory analyses will investigate early molecular  \n[https://www.researchprotocols.org/2026/1/e86737](https://www.researchprotocols.org/2026/1/e86737) JMIR Res Protoc 2026 | vol. 15 | e86737 | p. 1  \n(page number not for citation purposes)  \nJMIR RESEARCH PROTOCOLS Michalski et al  \nre","cbCaiigpwlDRtXAI","https://ap.wps.com/l/cbCaiigpwlDRtXAI","pdf",315271,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Introduction\n## Background","[{\"question\":\"What is the primary aim of the LOOPS study?\",\"answer\":\"To prospectively investigate the prognostic and predictive value of ctDNA in patients receiving PSMA radioligand therapy.\"},{\"question\":\"How are ctDNA samples collected and assessed in the trial?\",\"answer\":\"Blood samples for ctDNA analysis are collected longitudinally at baseline and after cycles 1, 2, 4, and 6, using standardized processing protocols.\"},{\"question\":\"What response endpoint does the study use to evaluate ctDNA?\",\"answer\":\"Baseline ctDNA’s prognostic and predictive value is assessed for treatment response based on imaging- and PSA-based criteria after 2 cycles of PSMA RLT.\"}]","Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy - Protocol for a Prospective, Longitudinal Multicenter Observational Study | PDF",1790101656,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/956974865cf1950e5071d559a39284a0.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f95c844a02d5e9de734517eda82d3ff.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0beed3c5751fe423197eb7c49d43213c.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf6794bc2673e9f149b4cb88fc6e545e.webp",980,1385]